Clementia
6,695 employees on LinkedIn · 2 known investors
Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
Investors · 2
Acquisitions · 2
Early investors' stakes continue via these dealsImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases. The company is a late-stage biotech enterprise collaborating with academic institutions and pharmaceutical partners to advance its pipeline.
In the news
Frequently asked questions
- What does Clementia do?
- Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
- Who are Clementia's investors?
- Clementia's investors include New Enterprise Associates (NEA), Ysios Capital.